Affiliation:
1. Medical Supplies Center of Chinese PLA General Hospital
Abstract
Abstract
Objective
To assess the safety, tolerability and pharmacokinetics of a single dose of SYHA1402 in Chinese healthy subjects.
Methods
This was a randomized, double-blind, placebo-controlled, single-ascending dose study in healthy subjects. Subjects received a single dose of 25mg (n = 4), 50mg (n = 8), 100mg (n = 8), 200mg (n = 8), 400mg (n = 8), 800mg (n = 6) or matching placebo (n = 12, 2 in each dose group). We assessed safety and tolerability throughout the study. The pharmacokinetic (PK) parameters of SYHA1402 were estimated using non-compartmental analysis.
Results
In all, 54 subjects were enrolled and completed the study. Specifically, there were no deaths, serious adverse events, or withdrawals from study due to adverse events. All treatment-emergent adverse events were mild. The most common drug-related adverse event was sinus bradycardia. The time to maximum concentration ranged from 1.13 to 2.25 h. The terminal elimination half-life range of SYHA1402 was 1.51 h to 4.70 h. SYHA1402 exhibited nonlinear PKs with less than dose-proportional increases in exposure after single oral doses of 25 mg to 800 mg. Fe0 − 72h from urine of SYHA1402 in each dose group from 25 mg to 800 mg was 64.08%, 57.97%, 59.28%, 24.64%, 8.49%, 7.15%, respectively.
Conclusion
Single dose of SYHA1402 was well tolerated and safe over the dose range of 25–800 mg. More than 50% of the unchanged SYHA1402 were excreted in urine within the dose range of 25–100 mg. With the dose increasing to 800 mg, the urine excretion amount of SYHA1402 gradually tends to saturation.
Trial registration number
NCT03988413 (https://www.clinicaltrials.gov/)
Trial registration date
June 17, 2019
Date of first patient’s enrollment:
August 5, 2019
Publisher
Research Square Platform LLC
Reference15 articles.
1. Aldose reductase expression is induced by hyperglycemia in diabetic nephropathy;Hodgkinson AD;Kidney Int,2001
2. Oxidative stress and diabetic vascular complications;Giugliano D;Diabetes Care,1996
3. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy;Dyck PJ;N Engl J Med,1988
4. Complications: neuropathy, pathogenetic considerations;Greene DA;Diabetes Care,1992
5. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes;Gabbay KH;Science,1966